GB201507926D0 - Improved treatments using oligonucleotides - Google Patents

Improved treatments using oligonucleotides

Info

Publication number: GB201507926D0
Authority: GB; United Kingdom
Prior art keywords: oligonucleotides; improved treatments; treatments; improved
Prior art date: 2015-05-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1507926.2A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ProQR Therapeutics BV

Original Assignee

ProQR Therapeutics BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-08

Filing date

2015-05-08

Publication date

2015-06-24

2015-05-08 Application filed by ProQR Therapeutics BV filed Critical ProQR Therapeutics BV

2015-05-08 Priority to GBGB1507926.2A priority Critical patent/GB201507926D0/en

2015-06-24 Publication of GB201507926D0 publication Critical patent/GB201507926D0/en

2016-05-09 Priority to PCT/EP2016/060344 priority patent/WO2016180784A1/en

Status Ceased legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
238000011282 treatment Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GBGB1507926.2A 2015-05-08 2015-05-08 Improved treatments using oligonucleotides Ceased GB201507926D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB1507926.2A GB201507926D0 (en)	2015-05-08	2015-05-08	Improved treatments using oligonucleotides
PCT/EP2016/060344 WO2016180784A1 (en)	2015-05-08	2016-05-09	Improved treatments using oligonucleotides

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1507926.2A GB201507926D0 (en)	2015-05-08	2015-05-08	Improved treatments using oligonucleotides

Publications (1)

Publication Number	Publication Date
GB201507926D0 true GB201507926D0 (en)	2015-06-24

Family

ID=53489357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1507926.2A Ceased GB201507926D0 (en)	2015-05-08	2015-05-08	Improved treatments using oligonucleotides

Country Status (2)

Country	Link
GB (1)	GB201507926D0 (en)
WO (1)	WO2016180784A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2810655C (en)	2004-06-24	2013-12-10	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
DK1993360T3 (en)	2005-12-28	2017-05-22	Vertex Pharma	SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
HRP20151137T1 (en)	2009-03-20	2015-11-20	Vertex Pharmaceuticals Incorporated	PROCEDURE FOR OBTAINING TRANSMEMBRANE CONTROLLER OF CYSTIC FIBROSE CONDUCTIVITY
IL265430B2 (en)	2012-02-27	2024-08-01	Vertex Pharma	Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
TWI794662B (en)	2016-03-14	2023-03-01	瑞士商赫孚孟拉羅股份公司	Oligonucleotides for reduction of pd-l1 expression
JP7557365B2 (en) *	2017-03-19	2024-09-27	スチョウサーナオミクスバイオファーマシューティカルズカンパニーリミテッド	Gemcitabine derivatives for the treatment of cancer
CN110740737A (en) *	2017-05-04	2020-01-31	赛诺菲	Methods for treating Alport syndrome
TWI840345B (en)	2018-03-02	2024-05-01	美商Ionis製藥公司	Modulators of irf4 expression
IL314102B2 (en) *	2018-08-02	2025-10-01	Dyne Therapeutics Inc	Complexes targeting transferrin receptor and uses thereof
WO2021062163A1 (en)	2019-09-27	2021-04-01	Disc Medicine, Inc.	Methods for treating myelofibrosis and related conditions
CA3177830A1 (en)	2020-05-13	2021-11-18	Maria BECONI	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP4189091A4 (en) *	2020-07-31	2024-10-02	Ractigen Therapeutics	Combinatory treatment of sma with sarna and mrna modulators
CA3235096A1 (en)	2021-11-17	2023-05-25	Disc Medicine, Inc.	Methods for treating anemia of kidney disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5652356A (en) *	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
WO1999050409A1 (en) *	1998-04-01	1999-10-07	Hybridon, Inc.	Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
US8389488B2 (en) *	2007-11-05	2013-03-05	Isis Pharmaceuticals, Inc.	Antidotes to antisense compounds
SI2852668T1 (en) *	2012-07-12	2016-09-30	Proqr Therapeutics Ii B.V.	Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell

2015
- 2015-05-08 GB GBGB1507926.2A patent/GB201507926D0/en not_active Ceased
2016
- 2016-05-09 WO PCT/EP2016/060344 patent/WO2016180784A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2016180784A1 (en)	2016-11-17

Publication	Publication Date	Title
IL256634A (en)	2018-02-28	Therapeutic oligonucleotides
GB201507926D0 (en)	2015-06-24	Improved treatments using oligonucleotides
GB201503408D0 (en)	2015-04-15	Oligonucleotides
AU367341S (en)	2016-02-29	Hairbrush
IL257921A (en)	2018-05-31	Combination comprising immunostimulatory oligonucleotides
LT3197456T (en)	2018-07-10	Cancer treatments
GB201502137D0 (en)	2015-03-25	Treatment
GB201608885D0 (en)	2016-07-06	Treatment
GB201522243D0 (en)	2016-01-27	Treatment
GB201511218D0 (en)	2015-08-12	Reservoir treatments
GB201504124D0 (en)	2015-04-22	Oligonucleotides
GB201519450D0 (en)	2015-12-16	Novel treatment
PL3329004T3 (en)	2020-10-05	Therapeutic oligonucleotides
GB201412011D0 (en)	2014-08-20	Treatments
GB201508841D0 (en)	2015-07-01	Treatment
SG11201700652PA (en)	2017-02-27	Modified antimir-138 oligonucleotides
GB201412976D0 (en)	2014-09-03	Hair treatments
GB201503008D0 (en)	2015-04-08	Treatment
GB201411027D0 (en)	2014-08-06	Treatment
GB201714330D0 (en)	2017-10-18	Oligonucleotides
GB201721384D0 (en)	2018-01-31	Surface Treatments
GB201412411D0 (en)	2014-08-27	Treatment
GB2555225B (en)	2020-12-09	Hydrocarbon-contamination treatment unit
GB201518349D0 (en)	2015-12-02	Treatment
GB201515739D0 (en)	2015-10-21	Treatment

Legal Events

Date	Code	Title	Description
2017-01-04	AT	Applications terminated before publication under section 16(1)